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ACR = American College of Rheumatology; cANCA = cytoplasmic antineutrophil cytoplasmic antibody; ds = double-stranded; ITP = idiopathic
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systemic lupus erythematosus.
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Introduction
B lymphocytes arising from haematopoietic stem cells pass
through a series of intermediate stages (pro-B, pre-B,
immature B and mature B cells); this gives rise to plasma
cells, which produce immunoglobulins. Although the major-
ity of immunoglobulins are concerned with defence against
the multitude of pathogens that surround and invade our
bodies, some, by virtue of their recognition of self targets
(autoantibodies), have the capacity to cause self harm or
autoimmune disease. The issue of the relative contributions
of T cells, B cells, cytokines and other elements within the
immune system has been debated for decades, but the
past 5 years have seen an upsurge of interest in the notion
that B cells are an integral part of the problem in autoimmu-
nity and that blocking them may be beneficial. The work of
Mathis and colleagues [1] suggesting a role for B cells in
the development of a form of experimental arthritis, and the
studies conducted by Edwards and colleagues [2,3]
describing patients with erosive rheumatoid arthritis (RA)
successfully treated with B cell depletion have provided
strong supporting evidence for this notion.
A number of markers, including CD19 and CD20, appear
early in the process of B cell development (at the pro-B or
pre-B cell stage). They remain present until the stage of
the mature B cell in the periphery, where conversion to a
plasma cell is associated with loss of CD20, although the
CD19 marker is still detectable. Much interest has
focused on the role of CD20 in B cell physiology but it
remains uncertain. Possible roles include its functioning as
a calcium channel subunit [4].
In this brief review we focus on results to date of attempts
to utilize B cell depletion based on the use of a chimeric
mAb that is specific for human CD20, namely rituximab
(MabThera®/Rituxan®; Roche Pharmaceuticals, Basel,
Switzerland; Genentech, South San Francisco, USA;
IDEC Pharmaceuticals, San Diego, USA), for the treat-
ment of patients with autoimmune diseases.
Rituximab as therapy for B cell lymphoma
The potential of mAbs as therapeutic agents has long been
postulated. In November 1997, rituximab was the first mAb
to be approved for the treatment of any malignancy, with
the US Food and Drug Administration granting it a license
for treatment of relapsed or refractory, low-grade B cell fol-
licular non-Hodgkin’s lymphoma (NHL) [5]. High rates of
B cell depletion are observed in patients receiving the stan-
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Abstract
The CD20 cell marker appears early in the process of B cell development. In this review we focus on
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chronic idiopathic thrombocytopaenia. More recent success has been demonstrated in patients with
rheumatoid arthritis and systemic lupus erythematosus.
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dard four weekly treatments of 375 mg/m2, with response
rates of around 60% [6–8]. This depletion is usually sus-
tained for 6–9 months and does not seem to be associated
with a higher rate of infectious complications. In addition,
molecular remission (i.e. remission of genetic mutations
that are often associated with haematological malignancies
such as B cell lymphomas) can occur and appears to be
correlated with clinical response [9]. The use of rituximab in
B cell lymphoma therapy has now been broadened; some
groups are using it to ‘purge’ B cells before stem cell col-
lection in peripheral blood stem cell transplantation [10]. It
is also being investigated as an adjuvant to more conven-
tional chemotherapy in more aggressive lymphoma and
other B cell malignancies [9], and as an adjuvant following
bone marrow transplantation [11].
Rituximab in autoimmune diseases
Following these encouraging results in patients with B cell
lymphoma, rituximab was used experimentally in other dis-
eases presumed to be due to B cell pathology. The first
autoimmune disease in which success was demonstrated
was chronic idiopathic thrombocytopenia (ITP). In ITP,
platelets are opsonized by autoantibodies (usually platelet-
associated IgG) and prematurely destroyed by the
reticuloendothelial system [12]. Approximately 25–30% of
patients develop a chronic disease that becomes refrac-
tory to conventional therapy (including corticosteroids,
intravenous immunoglobulin and splenectomy) [13]. Ritux-
imab, used as a single agent at the doses suggested in
NHL, has been observed to produce overall response
rates of 30–50% (i.e. significant elevations in platelet
counts sustained for 6 months or longer) [13–15]. Deple-
tion of peripheral blood B cells occurred rapidly, as
expected. In addition, rises in platelet counts were
observed very quickly, generally within 1 week of the first
rituximab infusion [13,14,16–18]. In the group of patients
described in the literature, clinical responses were not
associated with significant falls in levels of platelet-associ-
ated IgG, with only a minority of patients reaching levels
found in normal individuals [13,14]. This early rise in
platelets is thus unlikely to be secondary to removal of
antiplatelet antibodies. One alternative suggestion is that
opsonized B cells can inhibit Fc receptors on
macrophages and removal of IgG-coated platelets [13].
Similar success has been observed in patients with autoim-
mune haemolytic anaemia refractory to conventional
therapy [18–21] and in cold agglutinin disease [22–24].
Restoration of erythropoiesis has also been observed in
refractory cases of pure red cell aplasia after treatment with
rituximab [20,25,26]. Observed responses were of a
similar rapidity of onset to that seen in the patients with ITP.
Rheumatoid arthritis and rituximab
RA has classically been thought of as a predominantly
T cell mediated disease [27]. However, interest in the role
of B cells in RA has recently been generated. The strength
of this theory has been ratified by encouraging results with
rituximab-induced B cell depletion in RA patients.
In an initial study, five patients resistant to at least five
disease-modifying antirheumatic drugs received a B cell
depletion protocol based on rituximab (with intravenous
cyclophosphamide and oral prednisolone). All patients
achieved at least an American College of Rheumatology
(ACR) 50 response (three achieved an ACR 70
response). Immunoglobulin levels fell only modestly,
chiefly in the first 10 weeks. Levels of IgM rheumatoid
factor (RF) fell in all patients at varying rates [2]. This
earlier open label study was extended to include 22 RA
patients treated with five different protocols [3]. These
protocols attempted to assess a possible dose–response
relationship with rituximab and whether the inclusion or
omission of cyclophosphamide was relevant. Major
responses (i.e. ACR 50 or greater) were associated with
higher doses of rituximab (i.e. equal to or greater than a
total treatment dose of 600mg/m2) in combination with
cyclophosphamide. In these 22 RA patients, B cell deple-
tion (with rituximab/cyclophosphamide/prednisolone) had
a selective effect on autoantibody levels; IgA RF, IgG RF
and IgG anti-cyclic citrulinated peptide antibodies fell
more than their corresponding serum immunoglobulin
classes. Clinical relapse was associated with rises in
autoantibodies rather than only with return of B cells [28].
A multicentre randomized controlled trial has now shown
that protocols based on rituximab are effective in treating
patients with active RA [29]. Combination treatment with
rituximab and cyclophosphamide, and with rituximab and
methotrexate gave comparable results (i.e. ACR 50
responses of 45% and 50%, respectively) and were both
superior to rituximab alone (ACR 50 of 32%) [30].
Systemic lupus erythematosus and rituximab
B cell dysfunction has been thought to be critical in the
pathogenesis of systemic lupus erythematosus (SLE), with
evidence for direct pathogenic roles for at least some
autoantibodies, most notably anti-double-stranded
(ds)DNA [31]. Thus, the concept of B cell depletion as
treatment for SLE seems rational.
Initial trials have shown promising results. Anolik and
coworkers first reported their phase I/II trial of rituximab in
12 patients with SLE in 2001 [32], which was followed by
a total group of 18 patients in 2002 [33]. Significant B cell
depletion in the peripheral blood correlated with clinical
improvement (assessed using the Systemic Lupus Activity
Measure score). However, significant changes in anti-
dsDNA titres and complement levels were not observed.
In another open study, six SLE patients received a combi-
nation of two 500mg rituximab infusions, two 750mg
cyclophosphamide infusions and high-dose oral cortico-
steroids over a 2 week period [34]. All five patients whoS19
completed the study (one was lost to follow up at
3 months) improved clinically, from a median British Isles
Lupus Assessment global score of 14 at the start of the
study to a score of 6 after a period of 6 months. In four
patients, haemoglobin levels and erythrocyte sedimenta-
tion rate improved and in all five patients C3 levels
increased. In two patients, clinical remission lasted well
beyond the period of B cell depletion, and the patients
remained off further immunosuppressive therapy at
18 months of follow up. In the other patients, relapse
occurred with B cell repopulation. The changes in anti-
dsDNA levels varied between patients, with no consistent
trends observed.
These open label studies in SLE suggest that B cell deple-
tion based on rituximab is worthy of a randomized, double
blind, controlled trial. The international validation efforts,
conducted principally by the Systemic Lupus Erythemato-
sus International Collaborating Clinics group, have pro-
duced both activity and damage indices for this disease.
The British Isles Lupus Assessment index seems particu-
larly suitable for use in drug trials given its ability to distin-
guish activity (‘at a glance’) in each of eight organs or
systems. For a ‘quick fix’ the global score indices Systemic
Lupus Activity Measure and Systemic Lupus Erythemato-
sus Disease Activity Index are also available and widely
used. This topic has been reviewed elsewhere [35].
Use of rituximab in other autoimmune
diseases
There have also been a number of recent open studies
using rituximab in less common autoimmune diseases.
Five patients with refractory dermatomyositis received rit-
uximab as a single agent at four weekly doses of
100mg/m2 (two weekly doses for juvenile patients) [36].
Within 1–3 months, all patients experienced marked
increases in muscle strength with improvements in quanti-
tative scores between 20% and 60%. Dermatitis also
improved dramatically. All improvements were sustained
for at least 6 months.
Rituximab has also been used successfully in type II mixed
cryoglobulinaemia. Fourteen refractory patients were
treated with the standard 4 week NHL rituximab regimen
[37]. Only low-dose oral steroids were allowed as con-
comitant immunosuppressive therapy. Clinical improve-
ment was observed in the majority of patients at 6 months
of follow up, although cryoglobulins only became negative
in 30%. RF decreased in 61% and became negative in
23%, whereas C4 increased in 50% of patients.
One case report describes the successful use of rituximab
in Wegener’s granulomatosis [38]. The patient had failed
to remain in remission at 5 years despite multiple immuno-
suppressive regimens. After the standard 4 week rituximab
course (plus high-dose corticosteroids), full clinical remis-
sion with disappearance of cytoplasmic antineutrophil
cytoplasmic antibodies (cANCAs) was obtained. Nine
months after the course, despite the maintenance of com-
plete clinical remission, the cANCA titre started to rise
again, along with a rise in B cell numbers. Rituximab treat-
ment was thus repeated (without corticosteroids) and the
patient remained in complete clinical remission, with a
negative cANCA, at 8 months of further follow up.
Preliminary studies of patients with IgM antibody related
polyneuropathies were among the first to suggest the
benefit of rituximab in the treatment of autoantibody-asso-
ciated diseases [39]. One case report has also described
a successful outcome when rituximab was used therapeu-
tically in a rare case of myasthenia gravis developing after
a bone marrow transplant [40].
The broader picture: combination therapy
The results of many of these trials report a variable effect
on autoantibody levels despite effective B cell depletion.
CD20 is lost from B cells in their terminal differentiation
into plasma cells. Thus, many of the pathogenic plasma
cells may not be effectively removed and may continue to
produce antibodies. From these more recent trials of ritux-
imab in RA and SLE, it seems highly likely that therapy
with a combination of agents causing more widespread
depletion of B cells, and possibly of plasma cells (i.e. high
dose corticosteroids and cyclophosphamide), produces
more effective and durable results.
However, most patients relapse despite full-dose ritux-
imab, steroids and cyclophosphamide, and the question
has been raised as to whether the regimens used are still
not potent enough [34]. Clearly, further work must be
done to determine optimal dosing schedules. There have
been successful results after repeated treatment with rit-
uximab [3,38], but again this requires further assessment.
In one SLE patient, retreatment with rituximab alone was
associated with failure to deplete B cells because of a
specific immune response to rituximab itself (Leandro,
Edwards, Cambridge and Isenberg, unpublished data).
However, higher doses of rituximab, combination with
other cytotoxic therapies and repeat treatment would
inevitably raise the likelihood of increased toxicity in what
thus far appears to be a relatively safe treatment. Further-
more, until we follow up the patients already treated for
longer periods of time, we cannot know what the long-
term consequences will be.
In the majority of studies conducted to date only minimal
side effects were reported. These have mostly comprised
infusion reactions (fevers, chills and rigors), which usually
decrease with each subsequent reaction and can mostly
be prevented by premedication with paracetomol, an anti-
histamine and corticosteroids. There does not appear to
be a general trend toward excess infectious complica-
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tions. This obviously compares very favourably with our
conventional immunosuppressive treatments. However, all
patients with autoimmune diseases who have been
treated thus far with B cell depletion are patients who
have received and failed (usually multiple) conventional
immunosuppressive regimens. There is a need to compare
B cell depletion directly in clinical trials with our ‘standard
of care’ immunosuppressive regimens.
The exact mechanism of action of B cell depletion in
autoimmune disease is still unclear. The clinical state
improves over a number of months despite almost immedi-
ate B cell depletion [3]. Furthermore, this improvement
appears to be sustained for longer than the period of
B cell depletion. Work to elucidate this mechanism fully
would be greatly beneficial. Rituximab is known to deplete
B cells by antibody-dependent, cell-mediated cytotoxicity,
by complement mediated cell lysis and/or by apoptosis
[41]. Recent work conducted by Anolik and coworkers
[32] in SLE patients indicates that polymorphisms of Fcγ
receptors may contribute to the variability of B cell deple-
tion, at least in patients treated with lower doses of ritux-
imab. In patients with NHL, a correlation between
polymorphisms of Fcγ receptors and response to rituximab
has also been found [32].
Combination regimens with other biological agents are
also being investigated. Interleukin-12 has been used with
rituximab in patients with B cell NHL with some encourag-
ing preliminary results [42]. It is likely that other mAbs will
also be used in future studies.
Conclusion
As discussed above, the open label trials of B cell deple-
tion and the recently reported multicentre randomized
controlled trial in patients with RA [29,30] now point to
likely expansion in the use of this approach for patients
with aggressive disease, not least because its cost is less
than that of tumour necrosis factor-α blockers. B cell
depletion, rather than rituximab (anti-CD20) therapy alone,
offers the possibility of treating a range of autoimmune dis-
eases. It is not a cure in most cases and its long-term side
effects have not been fully elucidated. However, there now
appears to be sufficiently encouraging data from open
label studies in SLE, in particular, to encourage the under-
taking of larger controlled clinical trials.
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